CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage...
- Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in...
- Two clinical stage product candidates in development for the treatment of melanoma - - RAS mutant melanoma...
- Preclinical data presented at AACR demonstrate that combining IMM-1-104 with chemotherapies used in the...
CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage...
- Deep Cyclic Inhibitor of the MAPK pathway demonstrated strong tumor growth inhibition in preclinical studies...
- IMM-1-104 has been well-tolerated, demonstrating the potential for a differentiated safety profile - - 100...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.